Anti-Saccharomyces cerevisiae Antibodies and Autoimmune Diseases

Tsahi T. Lerman, Eytan Cohen, Ilan Krause

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The introduction of anti-Saccharomyces cerevisiae antibodies (ASCAs) in recent decades has provided a major diagnostic tool for differentiating between Crohn’s disease (CD) and ulcerative colitis (UC) in inflammatory bowel disease (IBD) patients. Furthermore, ASCAs may be useful in identifying relatives of IBD patients who are at risk of the development of the disease. Although ASCAs were claimed to be quite specific for CD, a growing number of studies have identified high levels of ASCAs in several other autoimmune diseases, such as Behcet’s disease, celiac disease, spondyloarthropathies, autoimmune liver diseases, and systemic lupus erythematosus. Therefore, we may not be dealing with a CD-specific antibody, but rather a panel of ASCA-associated diseases, of which CD is the prototype. The possible pathogenic potential of ASCAs requires further investigation, in both human patients and experimental animal models.

Original languageEnglish
Title of host publicationInfection and Autoimmunity
PublisherElsevier
Pages115-127
Number of pages13
ISBN (Electronic)9780323991308
ISBN (Print)9780323991315
DOIs
StatePublished - 1 Jan 2024

Keywords

  • ASCA
  • Behcet’s disease
  • Celiac disease
  • Crohn’s disease
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'Anti-Saccharomyces cerevisiae Antibodies and Autoimmune Diseases'. Together they form a unique fingerprint.

Cite this